Clinical Trial Update: Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of larotinib in subjects with impaired hepatic function, exploring PK in esophageal cancer and solid tumors (not yet recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Solid Tumor

Drugs mentioned

• Larotinib (larotinib)

Snippet

Sponsor: Sunshine Lake Pharma Co., Ltd. | Conditions: Esophageal Cancer, Advanced Solid Tumor | Phase 1 | Status: NOT_YET_RECRUITING